Fractyl Health, Inc. (NASDAQ:GUTS) Stock Now Rated "Hold" by Sell-Side Brokerages

Key Points

• Fractyl Health has a consensus “Hold” rating from five analysts: three buys, one hold, and one sell. The average 12-month price target is $66.00.
• Shares opened at $4.41, near the company’s 52-week low of $4.14 and well below its $29.34 high; the stock has a market capitalization of approximately $58.5 million.
• Fractyl Health reported a quarterly loss of $1.44 per share, beating analyst expectations of a $1.62 loss. Institutional activity was mixed, though BlackRock initiated a position valued at roughly $1.43 million.

Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) has been assigned a consensus recommendation of "Hold" from the five ratings firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $66.00.

A number of equities analysts have recently weighed in on the company. Weiss Ratings lowered Fractyl Health from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Thursday, September 3rd. Wall Street Zen downgraded Fractyl Health from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. Finally, Craig Hallum began coverage on Fractyl Health in a research note on Wednesday, July 1st. They set a "buy" rating and a $48.00 target price on the stock.

Fractyl Health Stock Down 0.2%

GUTS opened at $4.41 on Tuesday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 3.15 and a current ratio of 3.15. Fractyl Health has a fifty-two week low of $4.14 and a fifty-two week high of $29.34. The firm's fifty day moving average is $7.27 and its 200 day moving average is $8.12. The stock has a market cap of $58.48 million, a price-to-earnings ratio of -0.42 and a beta of 2.42.

Fractyl Health (NASDAQ:GUTS - Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($1.44) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.62) by $0.18. On average, sell-side analysts forecast that Fractyl Health will post -6.32 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Fractyl Health

Institutional investors have recently added to or reduced their stakes in the stock. Sanctuary Advisors LLC purchased a new position in Fractyl Health during the second quarter valued at $26,000. FNY Investment Advisers LLC increased its holdings in Fractyl Health by 84.3% in the 2nd quarter. FNY Investment Advisers LLC now owns 65,420 shares of the company's stock valued at $51,000 after acquiring an additional 29,920 shares during the last quarter. Accredited Investors Inc. purchased a new stake in Fractyl Health in the 1st quarter worth $46,000. PEAK6 LLC purchased a new stake in Fractyl Health in the 2nd quarter worth $159,000. Finally, BlackRock Inc. bought a new position in shares of Fractyl Health during the 2nd quarter valued at about $1,431,000.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage biotechnology company focused on developing therapies for metabolic diseases, including type 2 diabetes and obesity. The company's approach is based on targeting the biology of the gastrointestinal system and developing treatments intended to address underlying disease mechanisms rather than relying solely on chronic medication.

Fractyl Health's lead product candidate is Revita, an investigational, minimally invasive endoscopic procedure designed to resurface the duodenal lining.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.